BMJ  2003;326:1235 (7 June), doi:10.1136/bmj.326.7401.1235

Paper

Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials

¹ Department of Epidemiology and Public Health, University of Leicester, Leicester LE1 6TP, ² Sheffield Health Economics Group, School of Health and Related Research, University of Sheffield, Sheffield S1 4DA, ³ Infectious Diseases Unit, Leicester Royal Infirmary, Leicester LE1 5WW

Objective To review the clinical effectiveness of oseltamivir and zanamivir for the treatment and prevention of influenza A and B.

Design Systematic review and meta-analyses of randomised controlled trials.

Data sources Published studies were retrieved from electronic bibliographic databases; supplementary data were obtained from the manufacturers.

Selection of studies Randomised controlled, double blind trials that were published in English, had data available before 31 December 2001, evaluated treatment or prevention of naturally occurring influenza with zanamivir or oseltamivir (if given using the formulation and dosage licensed for clinical use), and reported at least one end point of relevance.

Review methods The main outcome measures were the median time to the alleviation of symptoms (for treatment trials) and number of flu episodes avoided (for prevention trials). Three population groups were defined: children aged 12 years and under; otherwise healthy individuals aged 12 to 65 years; and "high risk" individuals (those with certain chronic medical conditions or aged 65 years and older).

Results Seventeen treatment trials and seven prevention trials identified met the inclusion criteria. All trials included compared one of the drugs against placebo or standard care. Treatment of children, otherwise healthy individuals, and high risk populations with zanamivir reduced the median duration of symptoms in days respectively by 1.0 (95% confidence interval 0.5 to 1.5), 0.8 (0.3 to 1.3), and 0.9 (-0.1 to 1.9) for the intention to treat population. The corresponding results, in days, for oseltamivir were 0.9 (0.3 to 1.5), 0.9 (0.3 to 1.4), and 0.4 (-0.7 to 1.4). The effect of giving zanamivir and oseltamivir prophylactically resulted in a relative reduction of 70-90% in the odds of developing flu, depending on the strategy adopted and the population studied.

Conclusions Evidence from randomised controlled trials consistently supports the view that both oseltamivir and zanamivir are clinically effective for treating and preventing flu. However, evidence is limited for the treatment of certain populations and for all prevention strategies.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

Related Articles

Tamiflu and neuropsychiatric disturbance in adolescents

Simon R J Maxwell
BMJ 2007 334: 1232-1233. [Extract] [Full Text] [PDF]

An iatrogenic pandemic of panic

Luc Bonneux and Wim Van Damme
BMJ 2006 332: 786-788. [Full Text] [PDF]

Experts question wisdom of stockpiling oseltamivir

Andrew Cole
BMJ 2005 331: 1041. [Extract] [Full Text] [PDF]

Guidelines on neuraminidase inhibitors in children are not supported by evidence

Mkael Symmonds, Nicholas J Matheson, and Anthony Harnden
BMJ 2004 328: 227. [Extract] [Full Text]

Neuraminidase inhibitors for influenza A and B: Antivirals need to be protected from adverse conditions to retain effectiveness

Subhash C Arya and Nirmala Agarwal
BMJ 2003 327: 105-106. [Extract] [Full Text]

Neuraminidase inhibitors for influenza A and B: PROSE may be as useful as POEMs

Nick C Bradley
BMJ 2003 327: 105. [Extract] [Full Text]

Neuraminidase inhibitors for influenza A and B: Study showed benefits of treatment are marginal

Mark Oliver
BMJ 2003 327: 105. [Extract] [Full Text]

Preventing and treating influenza

Klaus Stöhr
BMJ 2003 326: 1223-1224. [Extract] [Full Text] [PDF]

Neuraminidase inhibitors treat and prevent flu
BMJ 2003 326: 0. [Full Text] [PDF]

Related external webpages:

NHS Health Technology Assessment Programme

This article has been cited by other articles:

• Clayton, T. C., Thompson, M., Meade, T. W. (2008). Recent respiratory infection and risk of cardiovascular disease: case-control study through a general practice database. Eur Heart J 29: 96-103 [Abstract] [Full text]  
• Martinez, F. J. (2007). Pathogen-directed Therapy in Acute Exacerbations of Chronic Obstructive Pulmonary Disease. Proc Am Thorac Soc 4: 647-658 [Abstract] [Full text]  
• Maxwell, S. R J (2007). Tamiflu and neuropsychiatric disturbance in adolescents. BMJ 334: 1232-1233 [Full text]  
• Committee on Infectious Diseases, (2007). Antiviral Therapy and Prophylaxis for Influenza in Children. Pediatrics 119: 852-860 [Abstract] [Full text]  
• Lim, W S (2007). Pandemic flu: clinical management of patients with an influenza-like illness during an influenza pandemic. Thorax 62: 1-46 [Full text]  
• Democratis, J., Pareek, M., Stephenson, I. (2006). Use of neuraminidase inhibitors to combat pandemic influenza. J Antimicrob Chemother 58: 911-915 [Abstract] [Full text]  
• McCullers, J. A. (2006). Insights into the Interaction between Influenza Virus and Pneumococcus. Clin. Microbiol. Rev. 19: 571-582 [Abstract] [Full text]  
• Doyle, A., Bonmarin, I., Levy-Bruhl, D., Strat, Y. L., Desenclos, J.-C. (2006). Influenza pandemic preparedness in France: modelling the impact of interventions. J. Epidemiol. Community Health 60: 399-404 [Abstract] [Full text]  
• Bonneux, L., Van Damme, W. (2006). An iatrogenic pandemic of panic.. BMJ 332: 786-788 [Full text]  
• van der Wouden, J. C., Bueving, H. J., Thomas, S., Linder, J. A., Bhat, N., Shay, D. K., Uyeki, T. M. (2006). Influenza-associated deaths among children.. NEJM 354: 1317-1318 [Full text]  
• Dolin, R. (2005). Influenza -- Interpandemic as Well as Pandemic Disease. NEJM 353: 2535-2537 [Full text]  
• Cole, A. (2005). Experts question wisdom of stockpiling oseltamivir. BMJ 331: 1041-1041 [Full text]  
• Moscona, A. (2005). Neuraminidase inhibitors for influenza.. NEJM 353: 1363-1373 [Full text]  
• Beigel, J. H. (2005). Avian influenza A (H5N1) infection in humans.. NEJM 353: 1374-1385 [Full text]  
• Teo, S S S, Nguyen-Van-Tam, J S, Booy, R (2005). Influenza burden of illness, diagnosis, treatment, and prevention: what is the evidence in children and where are the gaps?. Arch. Dis. Child. 90: 532-536 [Abstract] [Full text]  
• Jackson, D., Barclay, W., Zurcher, T. (2005). Characterization of recombinant influenza B viruses with key neuraminidase inhibitor resistance mutations. J Antimicrob Chemother 55: 162-169 [Abstract] [Full text]  
• Legoff, J., Guerot, E., Ndjoyi-Mbiguino, A., Matta, M., Si-Mohamed, A., Gutmann, L., Fagon, J.-Y., Belec, L. (2005). High Prevalence of Respiratory Viral Infections in Patients Hospitalized in an Intensive Care Unit for Acute Respiratory Infections as Detected by Nucleic Acid-Based Assays. J. Clin. Microbiol. 43: 455-457 [Abstract] [Full text]  
• Etuwewe, O., May, H., Bakhshi, S., Wood, A., Hughes, K. (2004). Outbreaks of influenza: a virus in vaccinated elderly residents. British Journal of Infection Control 5: 29-30 [Abstract]  
• Jeon, S. H., Kayhan, B., Ben-Yedidia, T., Arnon, R. (2004). A DNA Aptamer Prevents Influenza Infection by Blocking the Receptor Binding Region of the Viral Hemagglutinin. J. Biol. Chem. 279: 48410-48419 [Abstract] [Full text]  
• Jefferson, T. (2004). How to deal with influenza?. BMJ 329: 633-634 [Full text]  
• Harling, R., Hayward, A., Watson, J. M (2004). Implications of the incidence of influenza-like illness in nursing homes for influenza chemoprophylaxis: descriptive study. BMJ 329: 663-664 [Full text]  
• Kroenke, K., Logio, L. (2004). Update in General Internal Medicine. ANN INTERN MED 141: 213-220 [Full text]  
• Balicer, R. D, Huerta, M., Grotto, I. (2004). Tackling the next influenza pandemic. BMJ 328: 1391-1392 [Full text]  
• Symmonds, M., Matheson, N. J, Harnden, A. (2004). Guidelines on neuraminidase inhibitors in children are not supported by evidence. BMJ 328: 227-227 [Full text]  
• (2004). Other articles noted: 25 Jul 03 to 7 Nov 03. Evid. Based Nurs. 7: e1-1 [Full text]  
• (2003). Neuraminidase Inhibitors Are Effective but Costly. JWatch General 2003: 3-3 [Full text]  
• Oliver, M. (2003). Neuraminidase inhibitors for influenza A and B: Study showed benefits of treatment are marginal. BMJ 327: 105-105 [Full text]  
• Bradley, N. C (2003). Neuraminidase inhibitors for influenza A and B: PROSE may be as useful as POEMs. BMJ 327: 105-105 [Full text]  
• Arya, S. C, Agarwal, N. (2003). Neuraminidase inhibitors for influenza A and B: Antivirals need to be protected from adverse conditions to retain effectiveness. BMJ 327: 105-106 [Full text]  
• Stohr, K. (2003). Preventing and treating influenza. BMJ 326: 1223-1224 [Full text]  

Rapid Responses:

Read all Rapid Responses

relative risks

david baker
bmj.com, 7 Jun 2003 [Full text]

Marginal benefits

Mark Oliver
bmj.com, 7 Jun 2003 [Full text]

Why use expensive drugs?

Barry A Groves
bmj.com, 7 Jun 2003 [Full text]

The role of antivirals in the control of influenza

Subhash C Arya, et al.
bmj.com, 8 Jun 2003 [Full text]

NICE guidlines on the use of neuraminidase inhibitors in children are not supported by evidence

Mkael Symmonds, et al.
bmj.com, 18 Sep 2003 [Full text]